TY - JOUR
T1 - A technology evaluation of the Onyx Frontier drug-eluting stent
AU - Leone, Pier Pasquale
AU - Assafin, Manaf
AU - Scotti, Andrea
AU - Gonzalez, Maday
AU - Mignatti, Andrea
AU - Dawson, Kathryn
AU - Rauch, Judah
AU - Khaliq, Asma
AU - Bliagos, Dimitrios
AU - Latib, Azeem
N1 - Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: Onyx FrontierTM represents the latest iteration within the family of zotarolimus-eluting stents (ZES), designed for the treatment of coronary artery disease. Approval by the Food and Drug Administration was granted in May 2022, and Conformité Européenne marking followed in August 2022. Areas covered: We hereby review the principal design features of Onyx Frontier, highlighting differences and similarities with other currently available drug-eluting stents. In addition, we focus on the refinements of this newest platform as compared with previous ZES versions, including the attributes yielding its exceptional crossing profile and deliverability. The clinical implications related to both its newest and inherited characteristics will be discussed. Expert opinion: The nuances of the latest Onyx Frontier, together with the continuous refinement previously witnessed throughout the development of ZES, lead to a latest generation device ideal for a diverse spectrum of clinical and anatomical scenarios. In particular, its peculiarities will be of benefit in the settings often offered by a progressively aging population, such as high bleeding risk patients and complex coronary lesions.
AB - Introduction: Onyx FrontierTM represents the latest iteration within the family of zotarolimus-eluting stents (ZES), designed for the treatment of coronary artery disease. Approval by the Food and Drug Administration was granted in May 2022, and Conformité Européenne marking followed in August 2022. Areas covered: We hereby review the principal design features of Onyx Frontier, highlighting differences and similarities with other currently available drug-eluting stents. In addition, we focus on the refinements of this newest platform as compared with previous ZES versions, including the attributes yielding its exceptional crossing profile and deliverability. The clinical implications related to both its newest and inherited characteristics will be discussed. Expert opinion: The nuances of the latest Onyx Frontier, together with the continuous refinement previously witnessed throughout the development of ZES, lead to a latest generation device ideal for a diverse spectrum of clinical and anatomical scenarios. In particular, its peculiarities will be of benefit in the settings often offered by a progressively aging population, such as high bleeding risk patients and complex coronary lesions.
KW - Coronary artery disease
KW - Onyx frontier
KW - drug-eluting stent
KW - percutaneous coronary intervention
KW - zotarolimus
UR - http://www.scopus.com/inward/record.url?scp=85160714437&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85160714437&partnerID=8YFLogxK
U2 - 10.1080/17425247.2023.2216449
DO - 10.1080/17425247.2023.2216449
M3 - Article
C2 - 37203200
AN - SCOPUS:85160714437
SN - 1742-5247
VL - 20
SP - 689
EP - 701
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 5
ER -